UBS Group Raises Medline (NASDAQ:MDLN) Price Target to $57.00

Medline (NASDAQ:MDLN) had its price objective raised by analysts at UBS Group from $48.00 to $57.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. UBS Group’s price target suggests a potential upside of 14.90% from the stock’s previous close.

Several other brokerages have also issued reports on MDLN. Barclays began coverage on shares of Medline in a report on Monday, January 12th. They set an “overweight” rating and a $50.00 price target on the stock. Truist Financial initiated coverage on shares of Medline in a report on Monday, January 12th. They set a “buy” rating and a $52.00 price target for the company. Rothschild & Co Redburn set a $42.00 price objective on Medline in a research report on Monday, January 12th. Bank of America assumed coverage on Medline in a research report on Monday, January 12th. They issued a “buy” rating and a $50.00 target price for the company. Finally, Leerink Partners set a $56.00 price target on Medline in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $49.69.

Medline Stock Performance

Shares of Medline stock traded up $1.43 during trading on Thursday, reaching $49.61. 1,568,604 shares of the company’s stock were exchanged, compared to its average volume of 3,332,921. Medline has a 1-year low of $34.89 and a 1-year high of $50.88. The company has a 50-day simple moving average of $44.21.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share for the quarter, missing the consensus estimate of $0.24 by ($0.25). The company had revenue of $7.79 billion during the quarter, compared to analyst estimates of $7.52 billion. The company’s revenue for the quarter was up 14.8% compared to the same quarter last year.

Insiders Place Their Bets

In related news, Director Charles N. Mills acquired 2,579,310 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were bought at an average cost of $29.00 per share, with a total value of $74,799,990.00. Following the completion of the purchase, the director directly owned 2,441,379 shares in the company, valued at $70,799,991. The trade was a -1,870.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares in the company, valued at $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC bought a new stake in shares of Medline in the 4th quarter valued at $155,000. North Star Investment Management Corp. acquired a new stake in Medline in the fourth quarter worth $36,000. NBC Securities Inc. bought a new stake in Medline in the fourth quarter valued at $28,000. Pictet Asset Management Holding SA bought a new stake in Medline in the fourth quarter valued at $48,996,000. Finally, Teachers Retirement System of The State of Kentucky acquired a new position in shares of Medline during the fourth quarter valued at about $2,768,000.

Trending Headlines about Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Analyst upgrades — BMO raised its price target to $54 and gave an “Outperform” rating, signaling more upside from current levels. BMO raises PT to $54
• Positive Sentiment: Analyst upgrades — RBC raised its price target to $53 and also rates MDLN “Outperform,” reinforcing buy-side momentum following the results. RBC raises PT to $53
• Positive Sentiment: Revenue beat and constructive 2026 guidance — Q4 sales of ~$7.79B topped estimates and full‑year 2026 guidance calls for organic sales growth of 8–9% and Adjusted EBITDA of $3.5–3.6B; management highlighted $2.4B in new customer signings and completion of the IPO. Medline Reports Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Institutional demand and IPO momentum — filings and data show large institutional allocations and follow-on positioning by major investors, which supports liquidity and buy-side interest post-IPO. Quiver Quant: Medline Reports Strong 2025 Results
• Neutral Sentiment: Conference call / transcript — the earnings call transcript is available for detail on margin drivers, customer wins and cost assumptions; useful for active investors to parse the guidance assumptions. Earnings call transcript
• Neutral Sentiment: Valuation discussion — post-earnings coverage is re‑pricing MDLN into the public comps; several outlets are assessing valuation after the early share momentum. Yahoo: Assessing Medline valuation
• Negative Sentiment: EPS miss and profitability headwinds — MDLN reported ($0.01) EPS vs. a ~$0.24 consensus, missing estimates; Q4 net income fell ~37.7% year/year driven by higher cost of goods sold (tariffs) and IPO/operating expenses. MarketBeat: MDLN earnings summary
• Negative Sentiment: Margin pressure and cost volatility — higher tariffs, inventory/cost increases and continued investments (headcount, automation) are compressing margins near term; watch whether gross margin recovers versus expected cost headwinds. MassDevice coverage
• Negative Sentiment: Insider and sponsor sales noted — secondary transactions and some large sponsor sell‑side activity were disclosed around the IPO, which can add supply pressure even as institutions load positions. QuiverQuant insider & institutional activity

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.